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Ontogeny of bradykinin B2 receptors in the rat kidney: Implications for
segmental nephron maturation. Kinins modulate renal function, yet their
role in the developing kidney is largely unknown. To explore the devel-
opmental role of the kallikrein-kinin system, we examined the postnatal
ontogeny and intrarenal localization of B2 receptors in the rat. Northern
blot analysis and RT-PCR documented the expression of B2 receptor
mRNA in the kidney and extrarenal tissues of fetal, neonatal and adult
animals. The abundance of B2 receptor mRNA is 10- to 30-fold higher in
neonatal than adult tissues in the following order: kidney > heart >
aorta > lung > brain. Receptor autoradiography revealed a gradual shift
in the localization of bradykinin binding sites from the outer cortex in the
newborn to the outer medulla in weanling and maturing rats. The almost
complete displacement of [1251]tyr°-bradykinin by HOE-140 indicates that
the majority of kinin receptors in the developing kidney belong to the B2
type. Immunolocalization studies using antipeptide antibodies directed
against various portions of the receptor revealed that B2 receptors are first
expressed on the luminal aspect of the upper limb of S-shaped bodies and
differentiating cortical collecting ducts. In marked contrast, the metaneph-
nc mesenchyme, pretubular aggregates and glomeruli display weak or no
B2 receptor immunoreactivity. Following completion of nephrogenesis, B2
receptor expression shifts to both luminal and basolateral aspects of
connecting tubules and collecting ducts. The results demonstrate that
bradykinin B2 receptor gene expression is activated in the developing
kidney and cardiovascular system. The spatially restricted expression of B2
receptors in the differentiating epithelium of the distal nephron, the site of
kinin formation, supports the hypothesis that kinins are paracrine modu-
lators of segmental nephron maturation.
At least two types of bradykinin receptors exist, B and B2 [1],
of which the B2 type is regarded as the mediator of the physio-
logical actions of kinins, including the modulation of renal blood
flow and urinary sodium excretion, cellular growth, and the
inflammatory response [2]. B2 receptor cDNA and gene have
been cloned from rat uterus [3, 4], human lung, uterus and
placenta [5, 61, and mouse [7, 81. These studies have shown that
the human, rat and mouse B2 cDNAs share more than 80%
nucleotide sequence homology. The predicted protein encoded by
the B2 receptor gene belongs to the seven transmenihrane G
protein-coupled superfamily of receptors. Southern analysis has
revealed that rodent and human genomes contain a single B2 gene
[3—7].
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Analysis of the tissue distribution of B2 mRNA is consistent
with bradykinin binding sites in the kidney, uterus, vas deferens,
lung, heart, ileum, testis, and brain [3]. Molecular and biochemical
studies have shown that some of these tissues express a local
kallikrein-kinin system (KKS) [8, 9]. In the mature kidney, the
KKS plays an important role in the regulation of renal blood flow
and sodium excretion [10—12]. In the heart and blood vessels,
kinins preserve myocardial function and structure and attenuate
neointima formation following vessel injury [13, 14]. In the brain,
kinins appear to be involved in the central regulation of blood
pressure [15].
There is increasing awareness that, in addition to its vasoactive
actions, bradykinin can stimulate a mitogenic response in quies-
cent fibroblasts, vascular smooth muscle cells and glomerular
mesangial cells [16—19]. The growth-related effects of kinins are
receptor-mediated and are associated with activation of a G-
protein, phosphoinositide hydrolysis and intracellular calcium
mobilization [20]. Recent data indicate that tyrosine kinase-
dependent pathways are also stimulated by B2 receptors [211.
Kinin-stimulated cellular growth is observed in vivo during early
development. We and others [22—24] have reported that renal
kallikrein gene transcription and enzymatic activity are develop-
mentally up-regulated during the preweaning period in the rat. In
contrast, the expression and activity of kininase II, the major
kinin-degrading enzyme, are low in the fetal and neonatal kidney
[25, 26], suggesting intrarenal kinin accumulation during the
developing period. Blockade of B2 receptors with HOE-140
during neonatal development suppresses the maturational in-
crease in kidney DNA synthesis [27]. In addition, preliminary data
indicate that blockade of B2 receptors during fetal life results in
renal hypoplasia and abnormal tubular differentiation [28].
In spite of the accumulating evidence suggesting a developmen-
(a! role for the KKS, little if anything is known regarding the
developmental and tissue-specific expression of kinin receptors.
Taking advantage of the molecular cloning of the B2 receptor and
the recent development of specific antibodies directed to various
regions of the B2-receptor, in the present study we examined the
ontogeny and distribution of bradykinin B2 receptors during
segmental nephron differentiation.
Methods
RNA preparation and Northern blot analysis
Newborn (1, 5, 12 and 20 days of postnatal life) and adult male
(150 to 250 g) Sprague-Dawley rats (Charles River Laboratories)
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were used for the gene expression studies. Each age group
consisted of 10 to 14 rat pups obtained from 3 to 5 litters. The
following organs were harvested: kidney, heart, aorta, lung, brain
and liver. Tissues were snap frozen in liquid nitrogen and subse-
quently kept at —80°C until use. Tissue total RNA was extracted
using the guanidinium isothiocyanate-phenol-chloroform method
of Chomczynski and Sacchi [29]. Poly A RNA was isolated by
oligo-dT chromatography of total RNA. Poly A RNA (6 jg/
sample) was resolved by electrophoresis on 1% agarose gels
containing 2.2 M formaldehyde followed by a transfer to a
positively charged nylon membrane (GeneScreen Plus, NEN).
The probes consisted of a full-length (1.9 kb) rat B2 receptor
cDNA [4], and a human glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) cDNA (from American Type Culture). Radiola-
beling of the probes with 32P-dCTP was accomplished by the
random primer technique, and hybridization and posthybridiza-
tion washes were performed at 65°C as previously described [30].
Hybridization signals were quantitated by laser densitometry and
were factored for those of GAPDH to correct for differences in
RNA loading.
Reverse transcription-polymerase chain reaction (RT-PCR)
of B2 mRNA
RT-PCR of B2 receptor mRNA was performed as recently
described [30]. The RT mixture (12 j.d) contained 3 j.g of total
kidney RNA, I ng of random hexamers, 1 jil of 10 m'vi dNTP, 2 LI
of lOx RT buffer [200 mivi Tris-HC1, pH 8.4, 500 m'vi KCI, 15 mM
MgCl2] and 200 U of MLV reverse transcriptase Superscript II
(BRL). RT was performed using Perkin Elmer Gene Amp PCR
System 2400 (Cetus Instruments, Norwalk, CT, USA) at 37°C for
50 minutes and the RT enzyme was inactivated by heating at 70°C
for 10 minutes. The template mRNA was degraded by incubating
the samples with 2 U of E. coli RNase H at 37°C for 20 minutes.
cDNA was amplified from one fourth of the RT mixture by PCR
using B2 receptor gene-specific primers (25 pmol of each), I U of
thermostable DNA polymerase from The rmus aquaticus (Taq
polymerase), 5 jl of lOx PCR buffer and 1 pA of 10 mts dNTP (30
cycles; 94°C, I mm; 58°C, 2 mm; 72°C, 3 mm). Exponential
amplification of B2 receptor cDNA was documented at 15, 25 and
30 cycles of PCR. The upstream primer corresponds to nucleo-
tides 161 to 182 of rat B2 receptor eDNA [5'-AGAACATCTTF-
GTCCTCAGCG-3'], and the dowstream primer is complemen-
tary to nucleotides 714 to 733 of rat B2 receptor eDNA [5'-
CGTCTGGACCTCC'TTGAACT-3'] [3]. The predicted size of
the PCR product is 572 bp. The specificity of the product was
confirmed by obtaining two restriction fragments (268 and 304 bp)
following digestion of 0.5 ag of the product with 3 U of NcoI
restriction enzyme at 37°C for one hour and by Southern blotting
[30].
As an internal standard for the efficiency of amplification, one
fifth of the RT product was also used to amplify GAPDH mRNA
sequences. The upstream primer [5'-AATGCATCCTGAC-
CACcIAACTGC-3'] corresponds to nucleotides 524 to 547, and
the downstream primer [5 '-GGCGGCCATGTAGGCCATCTG-
GAG-3'] is complementary to nucleotides 1055-1078 of rat
GAPDH eDNA [31]. PCR conditions were as follows: 94°C, five
minutes; 55°C, one minute; 72°C, seven minutes. The predicted
size of the PCR product is 555 bp.
Table 1. Anti—peptide antisera raised against the intracellular and
extracellular domains of the rat B2 receptor
Peptide Domain5 Antibody
TIANNFDWLFGEVLC ED2 AS276C
DRYLAVKTMSMGRMC 1D2 AS277
CMGESVQMENSMGTLR 1D4 AS278
SAHNGTFSEVNC ED1 AS279
LHKTNCTVAE JDI AS280
KRFRKKSREVYQAISRK 1D4 AS281
KDYSDEGHNVTACVISY ED3 AS282
DTLLRLGVLSGC ED4 AS283
° The standard one-letter-code for amino acids is used
ED, putative extracellular domain; ID, putative intracellular domain
°AS. antiserum
B, receptor autoradiography
The commercial bradykinin analogue Tyr°-bradykinin (Sigma
Chemicals, St. Louis, MO, USA) was radioactively labeled with
['251]-iodine as previously described [32]. After labeling, the
iodinated peptide was separated from the unlabeled fraction by
high performance liquid chromatography. Rat kidney samples
were rapidly frozen in liquid nitrogen, sectioned (15 im thick) in
a cryostat at —30°C, mounted on slides precoated with polylysine
(Sigma), and stored in plastic boxes at —70°C until use. Before
incubation, the sections were warmed to room temperature,
freeze dried and washed with 0.05 M Tris-HCI buffer, pH 7.6
containing 0.1% bovine serum albumin, 1 mvt ethylenediamine
tetraacetic acid, 1 m ethylene glycol bis-(/3-aminoethyl ether)
tetraacetic acid and 20 rM captopril (washing buffer). Incubation
with 3 nM [1251]Tyr°-bradykinin in washing buffer supplemented
with 1 mM dithiothreitol and 140 rg/ml bacitracin (Sigma) was
performed overnight at 4°C. After incubation, the sections were
washed with cold washing buffer (3 >< I mm) and distilled water
(1 x 1 mm), dried rapidly with a fan and exposed to Kodak
Biomax photographic film for 72 hours at —20°C. Specificity of the
binding was assessed by incubating consecutive sections in the
presence of 3 jIM of unlabeled Tyr°-bradykinin or the B2 antago-
nist HOE-140.
Production of anti-peptide antibodies to the bradykinin B2-receptor
Eight peptide segments were selected from the corresponding
cDNA sequence of the rat B2 receptor [3] by the criteria of
hydrophilicity, antigenicity and relative location in the receptor
protein. In this way, peptides covering seven of the eight predicted
intra- and extracellular domains of the transmcmbrane-spanning
receptor were synthesized. The peptides were then covalently
coupled to keyhole limpet hemocyanine and used for the gener-
ation of eight polyclonal antisera (A5276 to AS283, Table I) in
rabbits following established immunization procedures. When
used on tissue sections, the staining pattern produced by the
antisera has revealed a receptor distribution that is in essence
congruent with the conventional autoradiographic visualization of
the B2 receptor [33]. Further, the antibodies strongly recognize
their corresponding antigens and crossreact both with the dena-
tured and the native B2 receptor [34].
Immunohistochemistty
Renal tissue from Holtzman rats at 1, 3, 5, 12, 22, 30 and 60 days
of postnatal life was obtained under ether anaesthesia and fixed in
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Fig. 1. Postnatal ontogeny of bradykinin B2 receptor expression evaluated by Northern blot analysis. Blots of kidney, heart and brain contain poly A RNA
(6 pg/sample). Aorta and lung blots contain total RNA (50 pg/sample). B2 receptor mRNA is 4.0-kb in size and is up-regulated during the preweaning
period in the kidney and cardiovascular system. Samples were collected on postnatal days 1, 5 and 20, and from adult rats (day 90). GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
periodate-lysine-paraformaldehyde buffered at pH 7.4 for 24
hours at room temperature [35]. After fixation the samples were
dehydrated in ethanol and embedded in Histosee (Merck; Darm-
stadt, Germany) as previously described [33]. Immunostaining was
performed according to the peroxidase/anti-peroxidase (PAP)
method of Sternberger et al [361 with modifications described
earlier [37, 381. Briefly, dewaxed tissue sections were rehydrated,
washed with 0.05 M Tris-0.15 M NaC1, pH 7.8 and treated with
absolute methanol/10% (vol/vol) H202 for 15 minutes each to
block residual pscudopcroxidasc activity. Anti-peptide antibodies
(AS276 to AS283, Table 1) were used as a pool combination,
prepared by mixing the eight different antisera (1:500 to 1:1000),
or individually (1:100 to 1:200). Antisera were diluted in washing
buffer containing 1% immunoglohulin-free bovine serum albumin
(Sigma). Incubation with the B2 receptor antisera was performed
overnight at 22°C in a water bath that was used as a moist
chamber, The second antibody (swine anti-rabbit IgG, Dako;
Carpinteria, CA, USA) at a dilution of 1:80, and the PAP complex
(Dako) at 1:100 were applied for 30 minutes each. The peroxidase
activity was visualized by incubating the sections in a 0.1% (wt/vol)
of 3,3'-diaminohenzidine (Sigma) and 0.03% (vol/vol) of H202
solution for 15 minutes in the dark.
Controls for the immunostaining procedure were prepared by
omission of the first antibody and its replacement by non-immune
rabbit serum at the same dilutions. Alternatively, the sections
were incubated with the pool mixture of anti-peptide antisera
(AS276 to AS283) in the presence of a large molar excess of the
same peptides (100 to 200 j.tg/ml) used for immunization. After
overnight competition the sections were washed and immuno-
stained as already described.
In viva binding of the bradykinin B2 receptor antagonist HOE-140
Newborn rats (day 1) were injected daily until day 8 with the
bradykinin B2 receptor antagonist HOE-140 (500 pg/kg body wt
dissolved in sterile 0.9% NaC1, s.c., N = 16). A control group was
performed by injecting the same number of rats with the vehicle
alone, On day 8, after 15 minutes of the last injection, the rats
were sacrified under ether anesthesia and the kidneys gently
removed and fixed with periodate-lysine-paraformaldehyde as
described above. Next, the tissue was dehydrated and embedded
in Flistosec or directly frozen and sectioned in a cryostat. SectiorLs
from both frozen (15 tm thick) and embedded material (5 to 7
jxm thick) were incubated with various polyclonal and monoclonal
antibodies raised against the B2 antagonist HOE-140: MHOI,
culture supernatant (1:100); MHO2, ascitic fluid (1:5,000); rabbit
antiserum AS255 (1:1000). The anti-antagonist antibodies have
been well characterized and used to visualize the B2 receptor ofl
tissue sections and on Western blots [33, 34, 39—43]. Controls
were carried out during the immunohistochemical procedure by
omission and replacement of the anti-antagonist antibodies by
non-immune rabbit serum or mouse lgG.
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Fig. 2. Ontogeny of bradykinin B2 receptors in
the kidney evaluated by reverse transcription-
polymerase chain reaction (RT-PCR). Ethidium
bromide-stained gels for B2-receptors (top) and
GAPDH (bottom). The apparent high
expression of B2 mRNA on day 20 is due to
higher amount of RNA used for the reverse5 2 transcription as indicated by a similar elevation
_____________________________
of GAPDH expression on day 20. Left lane:
DNA molecular size ladder (HaeLII digestion ofPostnatal 4X174).
Results
Ontogeny of bradykinin B2 receptor gene expression
The results of the RNA hybridization analysis are shown in Fig.
1. Northern blots of total and polyadenylated RNA isolated from
neonatal, weanling and adult rat tissues were probed with radio-
labeled B2 receptor or GA.PDH cDNAs. B2 receptor message is
detected in the kidney, heart, aorta, lung and brain (Fig. 1) but not
the liver (not shown). The size of the B2 receptor mRNA (4.0 kb)
is identical in developing and mature animals indicating the
absence of any developmentally regulated posttranscriptional
modification such as differential splicing or polyadenylation.
Figure 1 also shows that the relative abundance of B2 receptor
mRNA levels is considerably higher in the tissues of neonatal than
adult rats (kidney, 30-fold; aorta and heart, 15-fold; lung, 10-fold).
The exception to this is the brain, where B2 mRNA levels actually
increase fivefold with maturation. In addition, in the newborn B2
receptor mRNA levels are most abundant in the kidney and heart
followed by the aorta, lungs and brain (Fig. 1). The relatively
greater expression of B2 receptor mRNA in the kidney and
cardiovascular system is particularly apparent during the
preweaning period (birth to day 21). In contrast, GAPDH gene
expression remained relatively stable during postnatal maturation.
The temporal expression of B2 receptor mRNA was also
studied using a highly sensitive RT-PCR assay. As shown in
Figure 2, B2 receptor expression is detectable in the fetal kidneys
as early as day 18 of gestation, increase during the first three
weeks of postnatal life and declines in adulthood. The expression
of B2 mRNA during rat embryogenesis was not addressed in this
study. Based on the results of Northern blot analysis and RT-
PCR, we estimate that B2 mRNA levels are approximately 30-fold
higher in neonatal than adult kidneys. Collectively, these data
demonstrate that the bradykinin B2 receptor gene is subject to
considerable developmental and tissue-specific regulation.
Autoradiographic detection of the bradykinin B2 receptor
Autoradiography revealed the existence of bradykinin-binding
sites from the first day after birth with a gradual increase in the
intensity of the radiolabeling during the pre-wearting period, in
addition, a differential pattern of distribution was observed dur-
ing postnatal maturation (Fig. 3, A-L). In the kidney of i- to
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Fig. 3. Autoradiographic visualization of
bradykinin binding sites during postnatal
development. The left column represents the
radioactive labeling of bradykinin B2-receptors
using ['251}-Tyr°-bradykinin as a probe. The
right column shows the displacement of the
K L label produced by a molar excess of the B2
antagonist HOE-140 (A-H, x5; I-L, X3).
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Fig. 4. Immunovisualization of B2 receptors by
anti-peptide antibodies. Sections from periodate-
lysine-paraformaldehyde fixed tissue were
incubated with a mix (1:500) of eight
antipeptide antibodies directed to intra- and
extra-cellular domains of the B2 receptor. The
double arrows point to immunoreactive distal
nephron tubules. G, glomerulus; CCD, cortical
collecting ducts; MCD, medullary collecting
ducts, PST, proximal straight tubules (A-H,
X250). Reproduction of this figure in color was
made possible by a grant from Hoechst
Pharmaceuticals, Germany.
Fig. 5. High power immunovisualization of B2
receptors. At days 1 and 3 (A, C), the distal
upper limb of S-shaped bodies of the
developing cortex are immunolabeled at the
luminal side (small arrows). As maturation
proceeds (D, E, F), distal tubule segments
express immunoreactive B2 receptors on both
luminal and basolateral sides (large arrows) (A-
F, X 1300). Reproduction of this figure in color
was made possible by Hoechst Pharmaceuticals,
Germany.
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12-day-old rats, the B2 binding sites were mainly located in the
renal cortex (Fig. 3, A-H), whereas from day 30 to adult life, the
radioactive labeling was concentrated in the outer stripe of the
outer medulla (Fig. 3, K-L). At day 22, however, bradykinin
binding sites were found in both the cortex and in outer stripe of
the outer medulla (Fig. 3, 1, J).
Competition experiments on consecutive kidney sections
showed that virtually all [1251jTyr°-bradykinin binding was dis-
placed when the sections were coincubated with the radioligand
and a molar excess of unlabeled bradykinin (not shown) or the B2
antagonist HOE-140 (Fig. 3, right panel), indicating that the
bradykinin binding sites in the maturing kidney are almost
exclusively of the B2 type.
Immunovisualization of the B2 receptor by anti-peptide
antibodies
To further analyze the relationship between [1251]-Tyr°-brady-
kinin binding sites and authentic B2 receptors, we used an
immunolocalization technique by applying anti-peptide antibodies
raised to various segments of the B2 receptor protein. The results
for the individual antisera directed to the putative extra- and
intracellular domains of the B2 receptor were similar to those
obtained by mixing the various antisera. Immunovisualization
of B2 receptors by anti-peptide antibodies (Fig. 4, A-H) revealed
a pattern of staining that was largely congruent with that ob-
tained by autoradiography with [1251]-Tyr°-bradykinin or by the in
vivo labeling with the B2 receptor antagonist, HOE-140 (see
below).
Between day 1 and day 12, immunolabeled B2 receptors
(immunoreactive protein) were present in collecting ducts and in
distal nephron segments that in some cases could be clearly
recognized as connecting tubules (Fig. 4, A-D). Faint or no
immunoreactivity was observed in mature glomeruli and in prox-
imal convoluted tubules. From day 22, in addition to the presence
of immunoreactive B2 receptors in distal nephron segments and in
cortical collecting ducts, B2 receptors were concentrated in the
outer stripe of the outer medulla including the medullary rays
(Fig. 4, E-H). At this site, the immunoreactivity was mainly
localized in collecting ducts and to a less extent in the straight
portion of proximal tubules (Fig. 4, E-H). Further, B2 receptor
immunoreactivity was observed in the medullary collecting ducts
in the inner stripe of the outer medulla and in the inner medulla
(Fig. 4, F, H).
High power views of kidney sections obtained from days 1 and
3 revealed the presence of immunoreactive B2 receptors in the
upper limb of S-shaped nephrons and cortical collecting ducts of
the developing cortex. The immunolabeling of these structures
was exclusively associated to their luminal membranes (Fig. 5, A,
C). In contrast, well differentiated distal nephron segments and
cortical collecting ducts displayed immunoreactive B2 receptors
on both luminal and basolateral cell membranes. This stage-
dependent pattern of immunostaining was observed throughout
postnatal development (Fig. 5, B, D-F). In marked contrast to the
distinct immunolocalization of B2 receptors in the differentiating
tubular segments, no significant immunostaining could be identi-
fied in the subcapsular mesenchyme or pretubular aggregates.
Control slides showed no specific immunostaining when the
anti-peptide antiserum mixture was replaced by non-immune
serum (Fig. 6) or omitted (not shown). Furthermore, preabsorp-
tion of the antisera mixture with an excess (100 to 200 ig/ml) of
the same peptides used for immunization completely quenched
the specific immunostaining (not shown).
In vivo labeling of bradykinin B2 receptors
The daily injection of the B2 antagonist, HOE-140, to newborn
rats resulted in the in vivo labeling of renal structures in a similar
distribution to that demonstrated by autoradiography with [125I]
Tyr°-bradykinin or by immunocytochemistry with anti-peptide
antibodies. On day 8, the binding of HOE-140, revealed by
immunoeytochemistry with monoclonal and polyclonal antibodies
raised against HOE-140, was strong and uniform in the cortex and
less intense in the outer and inner medulla (Fig. 7A). No
immunoreactivity to HOE-140 was observed in the kidneys of rats
injected with the vehicle alone (Fig. 7B) or when the antibodies
directed to HOE-140 were replaced by non-immune serum (not
shown).
The HOE-140 immunoreactive nephron segments observed in
the cortex included cortical collecting ducts, connecting tubules
and some proximal tubules whereas no labeling was found in the
glomeruli. I-IOE-140 immunoreactivity was associated to both the
luminal and the basolateral cell membranes of distal nephron
segments such as collecting ducts and connecting tubules, includ-
ing those tubules located in the outermost cortex (Fig. 7, C-F). In
proximal tubules, HOE-140 immunoreactivity was mainly associ-
ated with the luminal side and particularly in reabsorption drop-
lets (Fig. 7G). Staining was also observed in isolated collecting
duct cells of the outer and inner medulla. In these cells, the
immunoreactivity usually occupied the whole cytoplasm of collect-
ing duct cells (not shown).
Discussion
The present study demonstrates that the bradykinin B2 receptor
gene is expressed in a developmentally regulated and tissue/cell-
specific manner. B2 receptor gene expression in the kidney is
highly activated in the newborn and throughout the first month of
postnatal life. Enhanced B2 receptor expression is also observed
in the developing heart and aorta, and the temporal postnatal
changes closely parallel those observed in the kidney. In contrast,
B2 receptor mRNA expression in the brain increases postnatally
and is not detectabie in the maturing liver. These differential
tissue-specific changes in gene expression suggest that B2 receptor
gene transcription is controlled by tissue-specific and develop-
mentally regulated trans-acting factors. Analysis of the 5'-up-
stream region of the rat B2 receptor gene reveals the presence of
putative cAMP- and interleukin-6 responsive elements [I.
Whether these regulatory regions are involved in the developmen-
tal activation of the B2 receptor gene is an interesting topic for
future investigation.
A contributing factor to the developmental regulation of the
bradykinin B2 receptor gene may be the age-related changes in
tissue kallikrein and local kinin levels. We have recently shown
that kallikrein-like activity in the kidney, heart and aorta is low in
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Fig. 6. Immunocytochemical control of the
immunostaining by anti-peptide antibodies. A. low
power view of immunoreactive B2 receptors at
day 22 by AS 276 (X150). B. Non-immune
rabbit serum applied at the same dilution
(>< 150).
the near-term fetus and increases dramatically (up to 20-fold)
during the preweaning period (birth to day 21) in the rat [22].
These changes in kallikrein activity are accompanied by parallel
changes in tissue immunoreactive kallikrein contents, mRNA
accumulation, and gene transcription rate [22—24]. The reciprocal
developmental expression of tissue kallikrein and B2 receptor
genes suggests that the maturational increase in tissue kallikrein/
kinin activity may exert a negative feedback effect on B2 receptor
expression.
The functional relevance of B2 receptor activation in the
developing animal is not entirely clear. Nephron growth is accom-
plished by both cellular hyperplasia and hypertrophy and both
processes are highly active during the latter stages of renal
organogenesis. On the other hand, postnatal cardiac growth is
mainly accomplished by cellular hypertrophy. Pharmacologic
blockade of B2 receptors with HOE-140 during the newborn
period in the rat results in a tissue-selective reduction in renal and
cardiac growth [27], consistent with the up-regulated expression of
B2 receptors in these tissues. When the kinin antagonist is
administered during fetal life, renal tubular ectasia and interstitial
fibrosis become also evident [28]. Thus, bradykinin B2 receptors
may be important for neonatal renal and cardiac growth.
In the adult animal, bradykinin increases renal blood flow and
promotes natriuresis, whereas B7 receptor blockade decreases
medullary blood flow and urinary sodium excretion [10—12]. In
the developing animal, intrarenal kinins are important in coun-
teracting angiotensin-mediated vasoconstriction [40]. The local-
ization of B2 receptors in the collecting ducts and the ability of
bradykinin to modulate sodium and water excretion [10—12] are
also in keeping with a role for B2 receptors in blood volume
homeostasis in the developing animal.
The results of the immunocytochemical localization of B2
receptors with anti-peptide antibodies provide important clues to
the function of kinins during segmental nephron maturation. The
lack of B2 receptor expression in the undifferentiated mesen-
chyme or pretubular aggregates indicates that kinins are unlikely
to be involved in mesenchymal-epithelial conversion nor to mod-
ulate the number of induced nephrons. Rather, the distinct and
restricted localization of B2 receptors in the differentiating epi-
thelium of stage II to IV nephrons strongly suggests that activa-
tion of B2 receptors may be more important for tubular growth!
differentiation and acquisition of function. This hypothesis is
strengthened by the fact that all the components of the KKS are
compartmentalized in the distal nephron. We have shown that
kallikrein-like immunoreactivity and mRNA are first expressed
in the distal end of the upper limb of S-shaped bodies (precursor
of connecting tubule) [23, 41]. Vascularization of inner cortical
glomeruli is temporally associated with an increased number of
connecting tubular cells expressing tissue kallikrein, further em-
phasizing the relationship between kinins and nephron differen-
tiation and acquisition of function [23, 41]. Preliminary studies
also indicate that low molecular weight kininogen, the substrate
for tissue kallikrein, is restricted to the terminal branches of the
ureteric bud and forming collecting ducts in a pattern that
overlaps with that of B2 receptors [42, 43]. Together, these data
indicate that the developing distal ncphron expresses a paracrine!
autocrine KKS.
The immunocytochemical studies in HOE-140-injcctcd new-
born rats confirm the predominant localization of B2 receptors in
the distal and collecting tubules. Furthermore, the results dem-
onstrate that HOE-140, a selective B2 antagonist, is capable of
reaching both proximal and distal sites within the developing
nephron. This information is particularly important in light of the
new data showing alterations of segmental nephron growth in
HOE-140-trcatcd rat pups [27, 28]. The presence of HOE-140
imrnunoreactivity in the proximal tubular cells, despite lack of
B2 receptors in this segment, can be explained by the finding
that HOE-140 undergoes endocytosis in proximal tubular cells
[321.
In summary, the present study documents enhanced expression
.
.
rt 
-
 
'1
 
.
1 
7.
, 
ci
 
?.
Ø
.rt
'- / 
-
 
s4
 
n
 
'I'.
: 
—
F:
 
I # 
0 ct
- 
S 
¶ 
a
 
-
 
I;.
- 
C 
A 
La
 
w
 
0.
 
—
1 
I 'p
 -
 
m
 
t 
S 
S 
7 
a
 
•
0 
It 
7:
 
I 
SM
 •
:' - 
"
V.
 
Sr
 
Is
 
-
 
•
 
•
 
-
 
':-
 
,
(4;
 
¼
 
-
a
 
C.
 
Fig. 7. In vivo labeling with the B2 antagonist HOE-140. Newborn pups were injected daily with HOE-140. On day 8 of postnatal life, kidney sections
were probed with antiHOE-i4O antibody. A. Whole kidney section showing the concentration of the immunoreactive antagonist in the renal cortex
(x12). B. Whole kidney section prepared from a rat injected with 0.9% sterile saline and then immunostained with anti-HOE-140 antibodies (x12).
C, D. Immunoreactive HOEi4O in collecting ducts (CD) and connecting tubules (CNT). The B2-receptor antagonist is concentrated at both luminal
(small arrows) and basolateral (large arrows) sides of collecting duct cells (x600), E, F. HOE-140 immunorcactivity in the luminal (small arrows) and
basal (large arrows) poles of distal nephron segments located at the superficial cortex (X600). G. Presence of immunoreactive HOE-140 in reabsorption
droplets of proximal tubules (PT). The small arrows point out the immunolabeling on the luminal membrane of distal nephron segments. G, glomerulus
(x600).
748 El-Dahr ci a!: Kinin receptors and kidney development
of bradykinin B2 receptors in the developing kidney. Expression of
B2 receptors is restricted to the cells destined to give rise to the
distal nephron, the site of kinin formation. The results suggest the
hypothesis that kinins may play an important role as paracrine
modulators of segmental nephron maturation.
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